Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Brunswick Corporation (BC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Brunswick Corporation — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while Brunswick Corporation trades at $75.42 (market cap $5.02B). The key difference: ACADIA Pharmaceuticals Inc. and Brunswick Corporation are close in size by market cap, and Brunswick Corporation pays a 2.28% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | BC | |
|---|---|---|
Market Cap | $4.49B | $5.02B |
Sector | Health | Consumer Cyclical |
52-Week High | $28.06 | $89.22 |
52-Week Low | $20.06 | $56.64 |
Enterprise Value | $3.69B | $7.19B |
Dividend Yield | — | 2.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
BC trades at $77.33, down 2.23% today, with a bearish technical signal and mixed earnings history. Revenue declined to $5.36B in 2025 with a net loss of $137.30M, though recent quarters beat expectations. The company maintains strong analyst support with a $86.40 consensus target and announced a $0.44 dividend for H1-26. Cash flow improved to a near-neutral -$11M in 2025 from deeper losses in prior years.
Outlook is cautious due to profitability challenges and high P/E of 73.92, but expansion news like Freedom Boat Club's 450th location offers growth potential. Risks include sustained negative margins and debt levels, while institutional buy ratings suggest confidence in a turnaround if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Brunswick Corporation
Brunswick Corp is the leader in several recreational sectors. The firm is the leading boat manufacturer, and its brands include Mercury and Mariner outboard engines
Read more on BC →
